Markers of Endothelial Dysfunction and Evaluation of Vascular Reactivity Tests in Behçet Disease

We assessed endothelial dysfunction (ED) in patients with Behcet disease (BD; n = 40) and healthy controls (n = 20). Serum lipid, homocysteine, asymmetric dimethylarginine (ADMA) and high-sensitivity C-reactive protein (hsCRP) levels, erythrocyte sedimentation rates (ESRs), and ultrasonographic flow-mediated dilatation (FMD) were measured. Mean hsCRP, ESR, homocysteine, and ADMA were significantly higher in the BD group (P < .001 for all). Patients with active BD had higher serum levels of hsCRP, homocysteine, and ESR compared with those in remission (P < .001, P < .001, and P = .005, respectively). Flow-mediated dilatation was significantly lower in patients with BD than in controls (P = .001). Flow-mediated dilatation correlated negatively with BD duration and serum ADMA levels (P < .001, r = −.745 and P < .001, r = −.682); a positive correlation was seen between serum ADMA levels and BD duration (P < .001, r = .552). Only stepwise multivariate regression analysis revealed BD duration to have a significant effect on FMD. Flow-mediated dilatation, in conjunction with markers of inflammation, may evaluate ED in patients with BD.

[1]  C. Ergin,et al.  Mean Platelet Volume in Recurrent Aphthous Stomatitis and Behçet Disease , 2014, Angiology.

[2]  Ş. Balta,et al.  Mean Platelet Volume as an Inflammatory Indicator in Behçet Disease , 2014, Angiology.

[3]  Ö. Yıldırımtürk,et al.  Evaluation of endothelial functions in patients with Behcet's disease without overt vascular involvement. , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[4]  N. Ermis,et al.  Elevated Oxidative Stress Markers and its Relationship With Endothelial Dysfunction in Behçet Disease , 2011, Angiology.

[5]  P. Home,et al.  The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease , 2010, Current cardiology reviews.

[6]  S. Yurdakul,et al.  Behçet’s Syndrome , 2010, Current rheumatology reports.

[7]  M. Gönül,et al.  Homocysteine levels in patients with Behçet’s disease and patients with recurrent aphthous stomatitis , 2009, Clinical Rheumatology.

[8]  O. Karabudak,et al.  Noninvasive assessment of impaired endothelial dysfunction in mucocutaneous Behçet’s disease , 2008, Rheumatology International.

[9]  R. Collins,et al.  Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis. , 2007, Clinical chemistry and laboratory medicine.

[10]  J. Lekakis,et al.  Interrelated modulation of endothelial function in Behcet's disease by clinical activity and corticosteroid treatment , 2007, Arthritis research & therapy.

[11]  Fehmi Baran,et al.  Homocysteine: an activity marker in Behçet's disease? , 2007, Journal of dermatological science.

[12]  M. Khan.  Homocysteine and cardiovascular disease , 2011 .

[13]  E. Yıldırım,et al.  Endothelial functions are more severely impaired during active disease period in patients with Behcet’s disease , 2007, Clinical Rheumatology.

[14]  M. Nazıroğlu,et al.  Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease. , 2006, Annals of clinical and laboratory science.

[15]  M. Kayıkçıoğlu,et al.  Endothelial functions in Behçet’s disease , 2006, Rheumatology International.

[16]  H. Oflaz,et al.  Impaired endothelium‐dependent flow‐mediated dilation in Behçet's disease: more prominent endothelial dysfunction in patients with vascular involvement , 2005, International journal of clinical practice.

[17]  N. Ermis,et al.  Vascular endothelial function and plasma homocysteine levels in Behcet's disease. , 2004, The American journal of cardiology.

[18]  B. Adam,et al.  Serum interleukin‐6, procalcitonin and C‐reactive protein levels in subjects with active Behçet's disease , 2004, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  D. Fliser,et al.  Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? , 2003, Kidney international. Supplement.

[20]  R. Boger.  T he emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor , 2003 .

[21]  M. Duman,et al.  Serum homocysteine level is higher in Behçet’s disease with vascular involvement , 2003, Rheumatology International.

[22]  G. Güvenen,et al.  Lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease. , 2003, Acta dermato-venereologica.

[23]  K. Aksu,et al.  A case of Behçet's disease with pulmonary arterial aneurysm and secondary amyloidosis. , 2002, Rheumatology.

[24]  F. Şahin,et al.  Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet's syndrome? , 2002, Clinical and experimental rheumatology.

[25]  H. Er,et al.  Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. , 2002, Mediators of inflammation.

[26]  M. Gürer,et al.  Serum homocysteine level in Behçet's disease. , 2002, Haematologia.

[27]  K. Aksu,et al.  Hyperhomocysteinaemia in Behçet's disease. , 2001, Rheumatology.

[28]  J. Kooner,et al.  Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome. , 2001, Journal of the American College of Cardiology.

[29]  P. Tsao,et al.  Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. , 1999, Circulation.

[30]  G. Ehrlich.  Vasculitis in Behçet's disease. , 1997, International reviews of immunology.

[31]  Ş. Kirazlı,et al.  Impaired haemostatic kinetics and endothelial function in Behçet's disease , 1996, Journal of internal medicine.

[32]  Ş. Kirazlı,et al.  Circulating Thrombomodulin as a Clue of Endothelial Damage in Behçet’s Disease , 1996, Thrombosis and Haemostasis.

[33]  J. Mege,et al.  Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. , 1993, The Journal of rheumatology.

[34]  International Study Group for Behçet's Disease,et al.  Criteria for diagnosis of Behcet's disease , 1990, The Lancet.

[35]  H. Pazarlı,et al.  Behçet's Disease , 1986, International journal of dermatology.

[36]  R. Ross,et al.  Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. , 1983, Circulation research.

[37]  R. Ross,et al.  Homocystinemia. Vascular injury and arterial thrombosis. , 1974, The New England journal of medicine.